Last reviewed · How we verify
sirolimus, mycophenolat mofetil, fluvastatin
This is a triple immunosuppressive and lipid-lowering regimen combining mTOR inhibition, inosine monophosphate dehydrogenase inhibition, and HMG-CoA reductase inhibition.
This is a triple immunosuppressive and lipid-lowering regimen combining mTOR inhibition, inosine monophosphate dehydrogenase inhibition, and HMG-CoA reductase inhibition. Used for Organ transplant rejection prophylaxis, Cardiovascular risk reduction in transplant recipients.
At a glance
| Generic name | sirolimus, mycophenolat mofetil, fluvastatin |
|---|---|
| Sponsor | University Hospital Schleswig-Holstein |
| Drug class | Immunosuppressive combination therapy with statin |
| Target | mTOR, IMPDH, HMG-CoA reductase |
| Modality | Small molecule |
| Therapeutic area | Immunology, Transplantation, Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Sirolimus inhibits mTOR signaling to suppress T-cell and B-cell proliferation. Mycophenolat mofetil inhibits IMPDH to selectively deplete guanosine nucleotides in lymphocytes. Fluvastatin reduces cholesterol synthesis and has pleiotropic immunomodulatory effects. Together, this combination provides potent immunosuppression with cardiovascular protection.
Approved indications
- Organ transplant rejection prophylaxis
- Cardiovascular risk reduction in transplant recipients
Common side effects
- Hyperlipidemia
- Anemia
- Thrombocytopenia
- Leukopenia
- Diarrhea
- Infection
- Nephrotoxicity
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: